Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

In vitro experience with cefonicid.

P Actor

    Reviews of Infectious Diseases
    |November 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Cefonicid demonstrates broad in vitro activity against many bacteria, similar to cefamandole. Susceptibility testing with cefonicid disks accurately predicts clinical efficacy for common gram-positive and gram-negative pathogens.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Susceptibilities of nontuberculosis mycobacterial species to amoxicillin-clavulanic acid alone and in combination with antimycobacterial agents.

    Antimicrobial agents and chemotherapy·1995
    Same author

    Efficacy of the hematoregulatory peptide SK&F 107647 in experimental systemic Candida albicans infections in normal and immunosuppressed mice.

    Immunopharmacology·1994
    Same author

    Indications that the erythrocyte receptor involved in enterotoxigenic Escherichia coli attachment is a sialoglycoconjugate.

    Journal of clinical microbiology·1985
    Same author

    Aridicins, novel glycopeptide antibiotics. I. Taxonomy, production and biological activity.

    The Journal of antibiotics·1985
    Same author

    Enoxacin: a potent inducer of filamentous Escherichia coli cells (a note).

    Acta microbiologica Hungarica·1985
    Same author

    Antimicrobial activity of SK&F 88070, an expanded-spectrum cephalosporin with high and prolonged levels in blood.

    Antimicrobial agents and chemotherapy·1984
    Same journal

    Fatal necrotizing otitis externa in a patient with AIDS.

    Reviews of infectious diseases·1991
    Same journal

    Use of the polymerase chain reaction for the specific and direct detection of Clostridium difficile in human feces.

    Reviews of infectious diseases·1991
    Same journal

    A new case of meningitis due to Pasteurella multocida.

    Reviews of infectious diseases·1991
    Same journal

    Disseminated pelvic actinomycosis presenting as metastatic carcinoma: association with the progestasert intrauterine device.

    Reviews of infectious diseases·1991
    Same journal

    Genetically engineered attenuated herpes simplex viruses.

    Reviews of infectious diseases·1991
    Same journal

    Role of altered drug metabolism in virus-drug interactions.

    Reviews of infectious diseases·1991
    See all related articles

    Area of Science:

    • Microbiology
    • Pharmacology
    • Infectious Diseases

    Background:

    • Cefonicid is a cephalosporin antibiotic with potential therapeutic applications.
    • Understanding its in vitro activity spectrum and susceptibility breakpoints is crucial for clinical guidance.
    • Comparison with existing antibiotics like cefamandole provides context for its efficacy.

    Purpose of the Study:

    • To evaluate the in vitro antimicrobial activity of cefonicid against a large panel of bacterial isolates.
    • To determine the correlation between cefonicid susceptibility disk tests and minimum inhibitory concentrations (MICs).
    • To establish interpretive breakpoints for cefonicid susceptibility testing and assess its pharmacokinetic profile.

    Main Methods:

    • In vitro susceptibility testing of over 5,000 bacterial isolates against cefonicid.

    Related Experiment Videos

  • Comparison of cefonicid activity with cefamandole and cephalothin using disk diffusion assays.
  • Determination of MIC values and correlation with zone sizes to establish breakpoints.
  • Evaluation of cefonicid stability against beta-lactamase hydrolysis and its affinity for penicillin-binding proteins.

    • Main Results:

    • Cefonicid exhibited high in vitro activity against a wide range of gram-positive and gram-negative bacteria.
    • Its spectrum of activity closely mirrored that of cefamandole, excluding specific resistant strains (e.g., MRSA, Pseudomonas).
    • Cefonicid susceptibility disk tests showed strong correlation with MIC values, with established breakpoints for susceptibility and resistance.
    • Pharmacokinetic data supported a 1g daily dose, with susceptible MICs ≤16 µg/ml and resistant MICs >32 µg/ml.

    Conclusions:

    • Cefonicid possesses broad-spectrum in vitro activity, making it a potentially valuable antibiotic.
    • Disk susceptibility testing for cefonicid is a reliable predictor of clinical efficacy.
    • Its stability to beta-lactamases and penicillin-binding protein affinity are comparable to cefamandole.